STAT+: Pharmalittle: We’re reading about Gilead’s HIV drug, FDA speeding review of a rare disease drug, and more
Written by
STAT News
Published
0
comments
0
min
CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's proven effectiveness